Abstract: The present invention relates to a transformant which is transformed to express Baeyer-Villiger monooxygenase (BVMO), a method for producing C5-C14 medium-chain ?-hydroxy fatty acids, ?,?-dicarboxylic acids, ?-amino fatty acids, or alcohols from C16-C20 long-chain fatty acids by biotransformation using the transformant, a method for producing a fatty acid derivative having an ester group which is introduced into the chain thereof from keto fatty acid using the BVMO, and novel ?-hydroxy fatty acids which are prepared by the method. Degradation products such as C5 to C14 ?-hydroxy fatty acids, ?,?-dicarboxylic acids, ?-amino fatty acids, alcohols can be produced in a large amount from C16 to C20 long-chain fatty acids contained in a medium by biotransformation using a transformant capable of expressing BVMO of the present invention. Therefore, it can be widely used to produce ?-hydroxy fatty acids, ?,?-dicarboxylic acids, ?-amino fatty acids or alcohols in a more safe and economic manner.

Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.

Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.

Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.

Abstract: Polyglycerol partial esters of a specific composition which are capable of solubilizing very hydrophobic, oil-soluble substances in aqueous solution are provided. The preparation and use of these polyglycol ether-free solubilizers in cosmetic formulations are also disclosed.

Abstract: Provided herein are dielectric fluids comprising at least one estolide compound of formula: in which n is an integer equal to or greater than 0; m is an integer equal to or greater than 1; R1, independently for each occurrence, is selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; R2 is selected from hydrogen and optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; and R3 and R4, independently for each occurrence, are selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched. Also provided herein are uses of dielectric fluids and electrical devices such as transformers that comprise a dielectric fluid comprising at least one estolide compound.

Abstract: Novel compounds of formula (1) wherein: A is especially a linear or branched divalent alkylene radical having between 1 and 10 carbon atoms, and Y is especially a hydrogen atom.

Abstract: A water-soluble metalworking oil agent is provided by blending the following components A, B, C and D: (A) at least one of a condensed fatty acid obtained by dehydration-condensing a ricinoleic acid, and a condensed fatty acid obtained by dehydration-condensing a monovalent carboxylic acid with an alcoholic hydroxyl group of a condensed fatty acid obtained by dehydration-condensing a ricinoleic acid; (B) an ester compound provided by a dehydration condensate of a monovalent or multivalent alcohol and a monovalent carboxylic acid; (C) an amine compound; and (D) water. A blend ratio of the component A is 10 mass % or more of a total amount of the oil agent and a blend ratio of the component B is 5 mass % or more of the total amount of the oil agent.

Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.

Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.

Abstract: There are provided compounds of formula (I): wherein X1 is O, NH, or S; X2 is O, NH, or S; and X3 is O, NH, or S; and wherein R, R1, T1 and T2 can represent various entities. Such compounds can be useful, for example, for preventing, palliating or treating various diseases such as heart diseases, respiratory diseases, treating inflammatory abnormalities, metabolic disorders or diabetes.

Abstract: A substantially pure Candida host cell is provided for the biotransformation of a substrate to a product wherein the host cell is characterized by a first genetic modification class that comprises one or more genetic modifications that collectively or individually disrupt at least one alcohol dehydrogenase gene in the substantially pure Candida host cell.

Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema.

Abstract: The present invention relates to a transformant which is transformed to express Baeyer-Villiger monooxygenase (BVMO), a method for producing C5-C14 medium-chain ?-hydroxy fatty acids, ?,?-dicarboxylic acids, ?-amino fatty acids, or alcohols from C16-C20 long-chain fatty acids by biotransformation using the transformant, a method for producing a fatty acid derivative having an ester group which is introduced into the chain thereof from keto fatty acid using the BVMO, and novel ?-hydroxy fatty acids which are prepared by the method. Degradation products such as C5 to C14 ?-hydroxy fatty acids, ?,?-dicarboxylic acids, ?-amino fatty acids, alcohols can be produced in a large amount from C16 to C20 long-chain fatty acids contained in a medium by biotransformation using a transformant capable of expressing BVMO of the present invention. Therefore, it can be widely used to produce ?-hydroxy fatty acids, ?,?-dicarboxylic acids, ?-amino fatty acids or alcohols in a more safe and economic manner.

Abstract: Provided are compounds and compositions derived from Pseudomonas sp., particularly, Pseudomonas fluorescens or Pseudomonas protegens and more particularly strain having the identifying characteristics of Pseudomonas ATCC 55799 having antimicrobial properties and particularly, antibacterial properties.

Abstract: The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ALS, by administering these compounds or pharmaceutical compositions to subjects in need thereof.

Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.

Abstract: An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy eicosapentaenoic acid (17,18-diHEPE) etc.), have activity of inhibiting neutrophil, thereby solving the object. The present invention unexpectedly remarkably inhibits infiltration into a tissue of, and activation of neutrophil found out at acute inflammation. The compound of the present invention is a compound which has not conventionally been known. Therefore, utility as a new therapeutic is provided.

Abstract: This invention refers to the synthesis and purification of 2 hydroxide derivatives of fatty acids, as well as to the separation method of its enantiomers (or optic isomers) [?] y [+], to the enantiomers themselves, to pharmaceutical compositions which include them, and to their use as medicines, as well as to an in vitro method of diagnosis/prognosis and evaluation of the potential use of the molecules of the invention in different pathologies, as well as their use for the regulation of certain enzymes and the study of their activity and effects.

Abstract: The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

Abstract: Castor oil was hydrolysed to castor fatty acids and self condensed to get a ricinoleic acid-based estolide of about 95 acid value. The carboxylic group of the estolide on subsequent esterification with linear or branched chain alcohols and also on acetylation of free hydroxy group yielded castor oil fatty acids based estolide esters and their acetates. All the products were evaluated for total acid number (TAN), viscosity, viscosity index, pour point, flash point, and copper strip corrosion and found to be potential lubricant basestocks.

Abstract: Cement compositions and processes for reducing air entrainment in a cement composition generally include mixing a hydraulic cement with a defoamer compositions including one or more organic acid ester polymers selected from an organic acid ester of polyethylene oxide polymer, an organic acid ester of polypropylene oxide polymer, and a mixture thereof. The compositions may further comprise an organic acid ester of an ethylene oxide-propylene oxide block copolymer.

Abstract: The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

Abstract: Provided herein are processes for preparing estolides and estolide base oils from fatty acid reactants utilizing catalysts. Further provided herein are processes for preparing carboxylic esters from at least one carboxylic acid reactant and at least one olefin.

Abstract: Provided herein are compositions comprising at least one estolide compound of formula: in which n is an integer equal to or greater than 0; m is an integer equal to or greater than 1; R1, independently for each occurrence, is selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; R2 is selected from hydrogen and optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; and R3 and R4, independently for each occurrence, are selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched. Also provided are uses of the compositions described herein.

Abstract: The present invention provides a novel macrocyclic compound exhibiting superior odor qualities and having a musk-like aroma, a method for producing the same, and a novel flavor or fragrance composition, and food products or beverages, fragrances or cosmetics, daily necessities or household goods and oral products using the novel macrocyclic compound. The invention relates to a compound represented by the formula (1), wherein each of wavy lines represents at least one of an E-configuration of C?C double bond and an Z-configuration of C?C double bond; m represents an integer of 0 to 10; and n represents an integer of 1 to 11, and n represents an integer of 1 to 11 when m is 0 to 4 or 6 to 10, and n is an integer of 1 or 3 to 11 when m is 5.

Abstract: The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer.

Abstract: Provided is a polyethylene glycol derivative which contains two PEG chains, which is bound to a diacylglycerol, which has high purity, and which enhances the stability of liposomes. Polyethylene glycol is represented by the following formula (1) and which is bound to a diacylglycerol: In Formula (1), R1 is a hydrocarbon group containing 1 to 7 carbon atoms, R2 is an alkyl or alkenyl group containing 9 to 21 carbon atoms, n is the average number of moles of added polyethylene glycol chains, 10?n?100, and X is a linker site between branched polyethylene glycol and the diacylglycerol and is represented by the following formula (2): —(CH2)l-Y—(CH2)m-??(2) In Formula (2), Y is an ether bond, an ester bond, a urethane bond, an amide bond, or a carbonate bond and l and m are an integer of 0 to 6.

Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.

Abstract: Provided herein are artificial membranes of mycolic acids. The membranes may be unsupported or tethered. These membranes are long lived and highly resistant to electroporation, demonstrating their general strength. The mycolic acid membranes are suitable for controlled studies of the mycobacterial outer membrane and can be used in other experiments, such as nanopore analyte translocation experiments.

Abstract: The invention describes novel isolated, purified, 10,17-dihydroxy-docoosahexaenoic acids, esters, derivatives and their preparation.

Abstract: Provided is a polyethylene glycol derivative which contains two PEG chains, which is bound to a diacylglycerol, which has high purity, and which enhances the stability of liposomes. Polyethylene glycol is represented by the following formula (1) and which is bound to a diacylglycerol: In Formula (1), R1 is a hydrocarbon group containing 1 to 7 carbon atoms, R2 is an alkyl or alkenyl group containing 9 to 21 carbon atoms, n is the average number of moles of added polyethylene glycol chains, 10 n 100, and X is a linker site between branched polyethylene glycol and the diacylglycerol and is represented by the following formula (2): In Formula (2), Y is an ether bond, an ester bond, a urethane bond, an amide bond, or a carbonate bond and 1 and m are an integer of 0 to 6.

Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis.

Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema.

Abstract: Leukotriene B4, 5S,12R-dihydroxy-6,8,10,14(Z,E,E,Z)-eicosatetraenoic acid, is a twenty carbon tetra-unsaturated fatty acid. No crystal forms of leukotriene B4 (LTB4) are known in the art. The present inventors have discovered a crystal form of LTB4 and the present invention therefore relates to crystal forms of LTB4 in general, and the novel crystal form A of LTB4 in particular.

Abstract: Provided herein are compositions comprising at least one estolide compound of formula: in which n is an integer equal to or greater than 0; m is an integer equal to or greater than 1; R1, independently for each occurrence, is selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; R2 is selected from hydrogen and optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; and R3 and R4, independently for each occurrence, are selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched. Also provided are uses of the compositions described herein.

Abstract: Novel compounds of formula (1) wherein: A is especially a linear or branched divalent alkylene radical having between 1 and 10 carbon atoms, and Y is especially a hydrogen atom.

Abstract: A method of improving the mechanical strength of polyurethane foams made from bio-based polyols, the polyol-containing compositions utilized in the method of the invention, and the polyurethane foams produced by the method of the invention are provided. The method of the invention involves the incorporation of aromatic polyester polyol in the polyol-containing composition used to manufacture the foams. In one embodiment, the aromatic polyester polyol is utilized in a polyol-containing composition which is employed in the manufacture of flexible polyurethane foam. In another embodiment, the aromatic polyester polyol transesterified with a natural oil-containing composition to form a transesterification reaction product that is utilized in a polyol-containing composition which is employed in the manufacture of flexible polyurethane foam.

Abstract: Methods and compositions for the production of oil, fuels, oleochemicals, and other compounds in recombinant microorganisms are provided, including oil-bearing microorganisms and methods of low cost cultivation of such microorganisms. Microalgal cells containing exogenous genes encoding, for example, a lipase, a sucrose transporter, a sucrose invertase, a fructokinase, a polysaccharide-degrading enzyme, a keto acyl-ACP synthase enzyme, a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty acid hydroxylase, a desaturase enzyme, a fatty aldehyde decarbonylase, and/or an acyl carrier protein are useful in manufacturing transportation fuels such as renewable diesel, biodiesel, and renewable jet fuel, as well as oleochemicals such as functional fluids, surfactants, soaps and lubricants.

Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used alone or in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin infection or wound healing.

Abstract: (PEG)-lipid conjugates and methods of preparation are disclosed herein. Methods of preparation may involve stepwise addition of small PEG oligomers to a glycerol backbone until a desired chain size is attained. Polymers resulting from the syntheses may be highly monodisperse. The resulting polymers may comprise branched polyethyleneglycol (PEG)-lipid conjugates. The present disclosure may provide several advantages such as simplified synthesis, high product yield and low cost for starting materials. The present synthesis method may be suitable for preparing a wide range of conjugates such as PEG lipid conjugates having a glycerol-like central backbone covalently attached to two or more monodisperse PEG chains and a lipid comprising a range of diesters made from fatty acids or bile acids.

Abstract: The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer.

Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.

Abstract: A compound of formula (I): wherein R represents a hydroxy substituted C24-C40 straight chain aliphatic group containing at least one double bond in the carbon chain; and at least one carbon in the chain is substituted with a hydroxy group. Such compounds are useful for detecting inflammation, inflammatory disorders and cancer in a subject, and can also be used in therapeutic applications including treatment and/or prevention of these conditions. Pharmaceutical compositions, combinations and supplements, as well as methods of treatment using the described compounds are therefore also described.

Abstract: Compositions and methods for controlling Limnoperna sp., particularly, golden mussels are provided using Pseudomonas sp. suspension or compounds and compositions derived from said suspension.

Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.

Abstract: Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state.

Abstract: The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.